ArticlePharmacoEconomics2026

Cost Effectiveness of Efanesoctocog Alfa Versus Factor VIII Extended Half-Life in Adolescent and Adult Patients with Hemophilia A in the USA.

Amy Dymond et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.